Tuesday, December 17, 2013

IDRA: Idera Pharmaceuticals ($3.04)

Idera Pharmaceuticals is a new holding.  Idera is a clinical stage biotechnology company developing a novel approach to the treatment of autoimmune diseases and certain genetically defined forms of B-cell lymphoma.  Their technology platform is based on nucleic acid therapies to inhibit over-reaction of Toll-like receptors.

Quick Facts:
135 million shares outstanding including warrants
84 million in cash
5M / Q burn rate
810 Million Market Cap
2031 for IMO-8400, 2034 IMO-9200 Patent Expiration

Clinical Trials:
Phase 2 Moderate to Severe Plaque Psoriasis.
Phase 1/2 B-Cell Lymphoma with MYD 88 L265P.

Catalyst:
Phase 2 for Psoriasis top line results in January.
Complete enrollment Phase 1/2 B-Cell Lymphoma?

Bottom Line:  Idera is unique with their technology based around Toll like receptors.  The company is currently working on the dosing for their IMO-8400 and MO-9200 technologies.  They have cash for now that should last until third quarter of 2015, and also patent protection until 2031 and 2034.

No comments:

Post a Comment